Molson Coors Beverage Company

▲ Bull Case

• ◆9%+ Total Shareholder Yield Is Self-Sustaining at Current Scale: Combined ~4.7% dividend yield + ~4.6% buyback yield = ~9% annual capital return, fully funded by $1.0–1.1B run-rate FCF. With ~5% annual share-count reduction, per-share underlying EPS grows ~5% from buybacks alone even if underlying earnings remain flat. At $42 entry, you're collecting a profitable wait while cost programs preserve earnings.
• ◆The $450M Cost Program + Premiumization Provide Operating-Leverage Upside: Q1 2026 +17% YoY underlying EBITDA growth (despite -2% revenue) proved the cost program is flowing through. At 50–66% realization, that adds $150–300M underlying EBITDA by 2027–2028 — a 6–12% structural uplift. Above-premium brands (Madri +15% Q3 2025, Peroni +25% Q3 2025) are gaining share and mix. Cost + mix together could stabilize underlying EPS in the $5.40–6.00 range, supporting 7.5x+ EV/EBITDA re-rating versus today's 5.7x.
• ◆US Volume May Stabilize Sooner Than Consensus Bears Expect: GLP-1 adoption rates are plateauing among early adopters; cannabis beverage category is still nascent ($2.8B by 2028). TAP's value-tier portfolio (Miller High Life, Keystone) benefits in trade-down recessions. Q1 2026 beat and distributor feedback on 12,000 new tap handles post-Bud Light suggest stabilization narratives are gaining credibility. If volumes land at -4% instead of guided -6 to -9%, that's a +$100–150M underlying EBITDA upside.

▼ Bear Case

• ◆The US Beer Category Is in Structural Secular Decline That Capital Return Cannot Offset: Volumes fell 6% in 2025 and are guided -6 to -9% for Q2 2026. GLP-1 (Ozempic, Wegovy, Zepbound) is reducing discretionary beverage consumption; cannabis beverages are scaling; spirits and RTDs are gaining wallet share. Even maintaining 24–25% US market share, the denominator is shrinking 6%+ annually. A $450M cost program ($150M/year run-rate) is insufficient to offset -6% volume decline in a $110B US beer market where TAP is ~60–65% of net revenue.
• ◆Residual $1.95B Americas Goodwill Remains at Impairment Risk: Q3 2025 already wiped $3.6B Americas goodwill. If US volumes accelerate to -8% or worse, or if guidance revises again, the remaining $1.95B could face further write-down. Equity would fall below $10B; the narrative shifts from capital-return story to balance-sheet deterioration. At that point, the dividend becomes vulnerable to a cut and buyback must pause, undermining the 9% yield thesis.
• ◆Dual-Class Governance + Family Control Limit Take-Out Optionality and Capital-Structure Flexibility: The Molson family controls Class A shares (voting); the public holds Class B (non-voting). This precludes activist intervention and majority M&A. If the business deteriorates, management has few levers. The result is a structurally trapped asset with no exit valve, forced to compound at low-single-digit or negative ROIC if category decline persists.

“The live debate is not whether Bud Light windfall persists (that debate is closed), but whether volume decline is stabilizing or accelerating. Bulls (35% of analysts, price targets $50–60) argue volume is decelerating, the cost program is real and over-delivers, and the 9% shareholder yield is the compounding engine; at 5.7x EV/EBITDA there's no rich downside and re-rating to 7.0–7.5x on stabilization is reasonable. Bears (25–30% of analysts, price targets $30–45) contend category decline is structural and accelerating; GLP-1 + cannabis are secular headwinds; the cost program will achieve only $150–200M in practice; further impairments are likely; and dual-class governance traps capital. The middle ground (consensus PT $51.47) acknowledges both: cost program + pricing stabilizes earnings at $5.40–5.80 through 2027–2028, volume lands at -4 to -5%, and the 9% yield supports Hold but multiple expansion is capped below 7x EV/EBITDA. The author notes Street is slightly more bullish than management's guidance, suggesting either Street is underestimating cost-program ramp or management's -11 to -15% EPS YoY guide is overly conservative—Q2–Q4 2026 results will resolve.”

• ◆Q2 2026 earnings (July/Aug): US volume trajectory clarification (stabilization narrative vs acceleration); underlying EBITDA +5 to +10% YoY vs flat-to-down = reset PT
• ◆Q3 2026 earnings (Oct/Nov): Cost program mid-point proof (150+ bps margin improvement vs <100 bps); determines cost-program credibility
• ◆Q1–Q2 2027 guidance cycle: 2027 EPS guidance and cost-program $100M+ cumulative realization; first evidence of earnings inflection
• ◆FY2027 full-year results (Feb 2028): Validates 24-month inflection cycle; underlying EBITDA margin 22–23% guidance sets 2028–2030 trajectory

• ◆GLP-1 accelerates beyond +3–5% annual beverage-volume headwind; TAP volumes fall -7 to -9% instead of -4 to -5% (Probability: 40–50%, Severity: Critical). Forces impairment review; stock -30 to -40%.
• ◆Further goodwill impairment ($1.5B+ Americas residual written down) in Q3–Q4 2026 or Q1 2027 (Probability: 30–35%, Severity: Critical). Equity drops below $10B; dividend cut risk emerges; stock -25 to -35%.
• ◆Cost program delivers only $200–250M of $450M target by 2027 due to execution friction or commodity rebound (Probability: 35–40%, Severity: High). EPS growth stalls at +1 to +2%; multiple re-rating reversed; stock -10 to -15%.
• ◆Dividend cut (10–15% base case; 35–40% bear case) if volume accelerates and impairment cycles repeat (Severity: High). Removes 4.7% yield cushion; capital-return thesis undermined; stock -15 to -20%.